Analyst Ratings For Biosyent Inc. (CVE:RX)
Today, Raymond James lowered its price target on Biosyent Inc. (CVE:RX) to C$10.00 per share.
There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Biosyent Inc. (CVE:RX) is Buy with a consensus target price of C$10.00 per share, a potential 33.33% upside.
Some recent analyst ratings include
- 3/22/2018-Biosyent Inc. (CVE:RX) had its Accumulate rating reiterated by Bloom Burton
Recent Trading Activity for Biosyent Inc. (CVE:RX)
Shares of Biosyent Inc. closed the previous trading session at 7,50 0,00 0,00 % with shares trading hands.